Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 High prevalence of trachoma particularly in developing regions
3.2.1.2 Increasing government initiatives and funding
3.2.1.3 Improved access to medicines
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of awareness about trachoma
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Macrolides
5.3 Tetracycline
5.4 Ophthalmic anti-infective
5.5 Sulfonamides
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Topical
Chapter 7 Market Estimates and Forecast, By Age-group, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Children
7.3 Adults
7.4 Geriatric
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AstraZeneca
10.2 Bausch Health Companies Inc.
10.3 Bayer AG
10.4 Eli Lilly and Company
10.5 F. Hoffmann-La Roche Ltd.
10.6 GlaxoSmithKline plc
10.7 Merck & Co., Inc.
10.8 Mylan N.V.
10.9 Novartis AG
10.10 Pfizer Inc.
10.11 Sanofi
10.12 Teva Pharmaceutical Industries Ltd.
